[Impact of growth-factor hormone control on the outcome of acromegalic cardiomyopathy].
OBJECTIVE
To observe the impact of growth-factor hormone control on the outcome of acromegalic cardiomyopathy by reviewing cases from our own center and from literatures.


METHODS
Two cases of acromegalic cardiomyopathy from Tongji hospital and 29 acromegalic cardiomyopathy cases with fully accessible data retrieved from PubMed and CNKI websites were included in present study for analysis. They were divided into "Controlled (< 5 microg/L)" or "Uncontrolled" group according to the serum level of growth factor hormone after treatments. Outcome of patients was evaluated by symptom, NYHA class, LV size and function status.


RESULTS
Incidence of patients with improved symptoms and cardiac performance was significantly higher in "Controlled" group (18/19) compared to those in "Uncontrolled" group (0/12; P < 0.01, chi(2) = 27.1). Post-treatment growth-factor hormone level < 5 microg/L is significantly associated with a satisfactory outcome of acromegalic cardiomyopathy (r = 0.935, P < 0.01).


CONCLUSIONS
Control of serum growth-factor concentration to a value < 5 microg/L is critical and associated with a favorable outcome for patients with acromegalic cardiomyopathy.
She
Qiu-fang
QF
Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Bai
Rong
R
Zhou
Qiang
Q
Yan
Jiang-tao
JT
Wang
Dao-wen
DW
D000172:Acromegaly / Q000150:complications / Q000628:therapy*; D000369:Aged, 80 and over; D009202:Cardiomyopathies / Q000209:etiology / Q000628:therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D019382:Human Growth Hormone